| Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies Y Cao, J Wang, F Jian, T Xiao, W Song, A Yisimayi, W Huang, Q Li, ... Nature 602 (7898), 657-663, 2022 | 1809 | 2022 |
| BA. 2.12. 1, BA. 4 and BA. 5 escape antibodies elicited by Omicron infection Y Cao, A Yisimayi, F Jian, W Song, T Xiao, L Wang, S Du, J Wang, Q Li, ... Nature 608 (7923), 593-602, 2022 | 1286 | 2022 |
| Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution Y Cao, F Jian, J Wang, Y Yu, W Song, A Yisimayi, J Wang, R An, X Chen, ... Nature 614 (7948), 521-529, 2023 | 666 | 2023 |
| Circular RNA vaccines against SARS-CoV-2 and emerging variants L Qu, Z Yi, Y Shen, L Lin, F Chen, Y Xu, Z Wu, H Tang, X Zhang, F Tian, ... Cell 185 (10), 1728-1744. e16, 2022 | 399 | 2022 |
| Fast evolution of SARS-CoV-2 BA. 2.86 to JN. 1 under heavy immune pressure S Yang, Y Yu, Y Xu, F Jian, W Song, A Yisimayi, P Wang, J Wang, J Liu, ... The Lancet Infectious Diseases 24 (2), e70-e72, 2024 | 275 | 2024 |
| Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy S Du, Y Cao, Q Zhu, P Yu, F Qi, G Wang, X Du, L Bao, W Deng, H Zhu, ... Cell 183 (4), 1013-1023. e13, 2020 | 239 | 2020 |
| Characterization of the enhanced infectivity and antibody evasion of Omicron BA. 2.75 Y Cao, W Song, L Wang, P Liu, C Yue, F Jian, Y Yu, A Yisimayi, P Wang, ... Cell host & microbe 30 (11), 1527-1539. e5, 2022 | 156 | 2022 |
| Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines Y Cao, A Yisimayi, Y Bai, W Huang, X Li, Z Zhang, T Yuan, R An, J Wang, ... Cell research 31 (7), 732-741, 2021 | 153 | 2021 |
| Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting A Yisimayi, W Song, J Wang, F Jian, Y Yu, X Chen, Y Xu, S Yang, X Niu, ... Nature 625 (7993), 148-156, 2024 | 147 | 2024 |
| Antigenicity and infectivity characterisation of SARS-CoV-2 BA. 2.86 S Yang, Y Yu, F Jian, W Song, A Yisimayi, X Chen, Y Xu, P Wang, J Wang, ... The Lancet Infectious Diseases 23 (11), e457-e459, 2023 | 129 | 2023 |
| Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents Y Cao, F Jian, Z Zhang, A Yisimayi, X Hao, L Bao, F Yuan, Y Yu, S Du, ... Cell reports 41 (12), 2022 | 90 | 2022 |
| Further humoral immunity evasion of emerging SARS-CoV-2 BA. 4 and BA. 5 subvariants F Jian, Y Yu, W Song, A Yisimayi, L Yu, Y Gao, N Zhang, Y Wang, F Shao, ... The Lancet Infectious Diseases 22 (11), 1535-1537, 2022 | 81 | 2022 |
| Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine Y Cao, X Hao, X Wang, Q Wu, R Song, D Zhao, W Song, Y Wang, ... Cell research 32 (1), 107-109, 2022 | 81 | 2022 |
| Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455–456 synergistically enhances antibody evasion and ACE2 binding F Jian, L Feng, S Yang, Y Yu, L Wang, W Song, A Yisimayi, X Chen, Y Xu, ... PLoS Pathogens 19 (12), e1011868, 2023 | 64 | 2023 |
| Protective effect of plasma neutralization from prior SARS-CoV-2 Omicron infection against BA. 5 subvariant symptomatic reinfection X Chen, Y Xu, Y Xie, W Song, Y Hu, A Yisimayi, S Yang, F Shao, L Geng, ... The Lancet Regional Health–Western Pacific 33, 2023 | 19 | 2023 |
| Neutralizing antibody evasion and receptor binding features of SARS-CoV-2 Omicron BA. 2.75 Y Cao, Y Yu, W Song, F Jian, A Yisimayi, C Yue, R Feng, P Wang, L Yu, ... Biorxiv 2022, 2007.2018. 500332, 2022 | 14 | 2022 |
| Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455-456 enhances antibody evasion and ACE2 binding F Jian, S Yang, Y Yu, W Song, A Yisimayi, X Chen, Y Xu, P Wang, L Yu, ... bioRxiv, 2023 | 10 | 2023 |
| Highly sensitive single-cell chromatin accessibility assay and transcriptome coassay with METATAC H Wu, X Li, F Jian, A Yisimayi, Y Zheng, L Tan, D Xing, XS Xie Proceedings of the National Academy of Sciences 119 (40), e2206450119, 2022 | 10 | 2022 |
| Humoral immunogenicity comparison of XBB and JN. 1 in human infections F Jian, A Yisimayi, W Song, J Wang, Y Xu, X Chen, Y Yu, X Niu, S Yang, ... | 4 | 2024 |
| Neutralisation activity of mucosal IgA against XBB sublineages and BA. 2.86 F Zuo, Y Cao, R Sun, A Yisimayi, L Du, F Bertoglio, M Schubert, C Guerra, ... The Lancet Infectious Diseases 24 (1), e7-e9, 2024 | 3 | 2024 |
